Corlanor (IVabradine HCl) Patent Expiration, LOE Window & CMS Spending

Corlanor (IVabradine HCl) by Amgen: FDA Orange Book core substance LOE 2027-06-12, 6 AB generics, $59.5M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN206143 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-06-12
Last Listed Patent or Exclusivity Date2027-06-12
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$59.5M
2024 Medicare Part D Spend$40.0M
2024 Medicaid Spend$19.5M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 22.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.